多巴胺受体DRD1变体的药理学特征和它们的性激活的探索
Chao Wu1, Kexin Wang1, Zhiyu Liu1
1State Key Laboratory of Biotherapy and Cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Biochemistry
|May 1, 2025
概括
在G蛋白结合受体 (GPCRs) 的遗传变异可以改变药物反应. 这项研究表明,全调节剂可以恢复功能丧失的多巴胺受体D1 (DRD1) 变体的功能,从而推进精确医学.
科学领域:
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- G蛋白结合受体 (GPCRs) 是关键的药物标,但遗传变异使药物的疗效复杂化.
- 了解遗传变异如何影响GPCR功能对于个性化医学至关重要.
研究的目的:
- 以多巴胺受体D1 (DRD1) 为模型,建立一个用于拯救GPCR中功能丧失 (LoF) 变异的框架.
- 研究DRD1基因变异的功能影响,并探索治疗恢复策略.
主要方法:
- 从遗传数据库和文献中鉴定了49种DRD1变异.
- 在HEK293细胞中评估了变异对膜表达,带结合和信号通路 (G蛋白和β-arrestin招募) 的影响.
- 利用结构分析来理解与变异相关的功能障碍.
主要成果:
- 大多数特征DRD1变种显示膜表达减少.
- 16种变体破坏了G蛋白信号传递,27种变体损害了β-止素的招募.
- 阿洛斯特基调节器成功地恢复了特定LoF变体 (例如,T371.46K,L662.46F) 中缺陷的G蛋白信号传递.
结论:
- DRD1基因变异显著影响受体功能,影响G蛋白和β-阿雷斯信号通路.
- 体调制提供了一个有前途的治疗策略,以恢复DRD1LoF变体的功能.
- 这项研究通过提供方法来解决由遗传变异引起的GPCR相关疾病,为精准医学做出了贡献.
更多相关视频
07:41Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
Published on: June 5, 2017
9.8K
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
8.8K
相关概念视频
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.5K
01:29The Two-State Receptor Model
1.8K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.8K
01:29Drug-Receptor Interactions
4.7K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.7K
01:25Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
01:08Allosteric Regulation
57.4K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.4K
01:25Adrenergic Agonists: Indirect-Acting Agents
1.4K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.4K